[HTML][HTML] Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: a case-control study
LV Cooper, TB Erbeto, AA Danzomo… - The Lancet Infectious …, 2024 - thelancet.com
Summary Background Between 2018 and 2022, Nigeria experienced continuous
transmission of circulating vaccine-derived type 2 poliovirus (cVDPV2), with 526 cases of …
transmission of circulating vaccine-derived type 2 poliovirus (cVDPV2), with 526 cases of …
[HTML][HTML] Novel oral polio vaccine type 2 use for polio outbreak response: A global effort for a global health emergency
FD Kurji, AS Bandyopadhyay, S Zipursky, LV Cooper… - Pathogens, 2024 - mdpi.com
A sharp rise in circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks in the years
following the cessation of routine use of poliovirus type 2-containing oral polio vaccine and …
following the cessation of routine use of poliovirus type 2-containing oral polio vaccine and …
[HTML][HTML] Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to< 5 years and lot-to-lot consistency of the immune response …
M Ochoge, AC Futa, A Umesi, L Affleck, L Kotei… - The Lancet, 2024 - thelancet.com
Background Novel oral poliovirus vaccine type 2 (nOPV2) has been engineered to improve
the genetic stability of Sabin oral poliovirus vaccine (OPV) and reduce the emergence of …
the genetic stability of Sabin oral poliovirus vaccine (OPV) and reduce the emergence of …
[HTML][HTML] Notes from the Field: House-to-House Campaign Administration of Inactivated Poliovirus Vaccine—Sokoto State, Nigeria, November 2022
O Biya - MMWR. Morbidity and Mortality Weekly Report, 2023 - cdc.gov
Background Routine administration of 1 dose of IPV at age 14 weeks, which was
recommended by GPEI following the switch, provides protection against paralysis caused by …
recommended by GPEI following the switch, provides protection against paralysis caused by …